CHI Insight Pharma Reports Research

CHA Advances Reports are a service of Cambridge Healthtech Advisors. Advances Reports are written by experts who collaborate with CHA to provide a series of reports that evaluate the salient trends in pharmaceutical technology, business, and therapy markets.

Advances Reports offer:
  • Current information and analysis of R&D technologies, therapeutic markets, and critical business issues.
  • Analysis of the probability of success for various applications of each technology.
  • Interviews with key personnel in companies at the forefront of technological advances.
  • Competitive insight on the business strategies and activities of key companies.
CHI Insight Pharma Reports Research
 

List of reports from CHI Insight Pharma Reports Research

< prev 1    
Ocular Disorders: Rising Therapeutics, Technologies, and Devices
10/1/2014 | published by: CHI Insight Pharma Reports
... dry) and devling into Anti-VEGF therapies in chapter 2. Further providing substantial weight to this report, several companies were interviewed on their approach to targeting wet and dry AMD, thier strategies for seeking alternative therapeutic ...  |  read more...
USD 1,995
Cancer Immunotherapy Report
9/1/2014 | published by: CHI Insight Pharma Reports
... once just a dream in the minds of physicians, clinicians and patients, but only recently (2010s era) has it actually been within reasonable reach. Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies ...  |  read more...
USD 2,495
Biomarkers in Alzheimer's Disease
8/1/2014 | published by: CHI Insight Pharma Reports
... Disorders, this report focuses on the Alzheimer’s Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing the ...  |  read more...
USD 699
Biomarkers in Parkinson's Disease
8/1/2014 | published by: CHI Insight Pharma Reports
... Neurodegenerative Disorders, this report focuses on the Parkinson’s Disease space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With regards to employing ...  |  read more...
USD 699
Biomarkers in Amyotrophic Lateral Sclerosis
8/1/2014 | published by: CHI Insight Pharma Reports
... a Diagnostic Approach to Neurodegenerative Disorders, this report focuses on the ALS space featured in the parent report, highlighting several biomarker targets under investigation and the progress that has been made in the industry. With ...  |  read more...
USD 699
Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders
7/1/2014 | published by: CHI Insight Pharma Reports
... development. Biomarkers have been a heavily studied topic of interest, and recently on the rise is the interest in neurodegenerative disorders. Although there are many techniques used to track neurodegenerative disease progression, this report will ...  |  read more...
USD 2,495
Antibiotic Renaissance: Technology and Market Advances in the War against Drug-resistant Bacteria
6/1/2014 | published by: CHI Insight Pharma Reports
... covers evolutionary growth of antibiotic resistant bacteria with a focus in research aspects, commercial aspects, market aspects, and trends in antibiotic resistance. Antibiotic resistance has a historical presence in the big pharma industry (documentation of ...  |  read more...
USD 2,495
Digital Pathology Insights: Imaging Technologies, Expert Perspectives, Standardization, and Current Outlooks Overview
5/5/2014 | published by: CHI Insight Pharma Reports
... it is a relatively new space in heavy pursuit of research due to its versatility and stability, properties that are unique to miRNAs compared to other RNA components. miRNA's non-coding nature and ability to affect ...  |  read more...
USD 2,495
Vaccines: The End of Illness Overview
4/10/2014 | published by: CHI Insight Pharma Reports
... efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing ...  |  read more...
USD 2,495
MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview
4/1/2014 | published by: CHI Insight Pharma Reports
... it is a relatively new space in heavy pursuit of research due to its versatility and stability, properties that are unique to miRNAs compared to other RNA components. miRNA's non-coding nature and ability to affect ...  |  read more...
USD 2,495
Molecular Diagnostic Market and Testing
2/1/2014 | published by: CHI Insight Pharma Reports
... and clinicians in the cancer and prenatal space. This report focuses on market background of the areas that are covered, including lung, breast, thyroid and blood cancers (specifically leukemia and lymphoma), as well as pre-conception ...  |  read more...
USD 2,495
Prenatal Diagnostics: Invasive testing, noninvasive testing, and rising maternal screening methods for preeclampsia and preterm labor
12/1/2013 | published by: CHI Insight Pharma Reports
... preeclampsia and preterm labor. This report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare. Although covering standard invasive procedure, this report focuses ...  |  read more...
USD 2,495
Epigenetics: Emerging Targets, Available Technologies, Expert Interviews, and an Epigenetic Community Perspective - Overview
12/1/2013 | published by: CHI Insight Pharma Reports
... mostly pertaining to epigenetic targets, and the reasons they are being investigated. Several companies have kindly disclosed several strategies, methods, and techniques that they use for either target identification or technology development. Report Features Include: ...  |  read more...
USD 2,495
Macrocycles: Discovery, Development & Technologies - Overview
12/1/2013 | published by: CHI Insight Pharma Reports
... what macrocycles are and the pharmacokinetic properties they exhibit Reviews specifics in technologies and current research in development Detailed descriptions of company overviews, technology platforms, benefits, challenges, competitive advantages, partnerships and future aspirations Macrocycles are ...  |  read more...
USD 2,495
Digital PCR Technology Report: An Insight to Vendors, Costs & the End User Community
5/1/2013 | published by: CHI Insight Pharma Reports
... is a new application in research and development allowing for higher sensitivity and specificity than real-time PCR. This allows researchers to closely examine rare genetic mutations (including single nucleotide polymorphisms), copy number variations, viruses, prenatal ...  |  read more...
USD 2,495
Advances in Clinical Genome Sequencing and Diagnostics: Implementing Advances in Next-Gen Sequencing to Clinical Diagnostics and the Challenges of Genome Interpretation
3/1/2013 | published by: CHI Insight Pharma Reports
... and business models. Aspects discussed and presented include: Progress in clinical genome sequencing. Organizations leading the way in generating clinical data and its interpretation. Determining the causality of documented variants in genetic disease. Clinical genome ...  |  read more...
USD 2,495
Therapies for Solid Tumors: Pipelines, Markets, and Business Considerations
9/1/2012 | published by: CHI Insight Pharma Reports
... of emerging drugs—for treatment of solid tumors, discussing: The various types of solid tumors that are the focus of the most pharmacological effort, including information about the specific disease, its incidence and epidemiology, current treatment ...  |  read more...
USD 2,495
The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
6/1/2012 | published by: CHI Insight Pharma Reports
... strategies. Following a review of the business environment and market forces, this report examines: The state of the art, and the needs and direction, of antibody technology today Antibody conjugates and other payloads: construction, clinical ...  |  read more...
USD 2,495
R&D Trends Melanoma - Drug resistance provides an opportunity for drug developers
5/15/2012 | published by: CHI Insight Pharma Reports
... in Phase II trials. Early-stage developers are focusing on new targets in the MAPK pathway and immunomodulator targets such as PD-1 in an attempt to limit acquired resistance. Features and benefits In-depth analysis of melanoma ...  |  read more...
USD 3,800
Treatment Algorithms: Rectal Cancer – Inclusion of chemoradiation can influence treatment and prescribing trends
4/26/2012 | published by: CHI Insight Pharma Reports
... off patent over the forecast period and the approval of new therapies, treatment of this growing market is set to evolve. Features and benefits Disease overview assessing, etiology, risk factors, screening procedures, and patient segmentation ...  |  read more...
USD 7,600
Treatment Algorithms: Colon Cancer – Treatment dictated by stage, prior therapy, and reimbursement
4/26/2012 | published by: CHI Insight Pharma Reports
... come off patent over the forecast period and the approval of new therapies, treatment of this growing market is set to evolve. Features and benefits Disease overview assessing, etiology, risk factors, screening procedures, and patient ...  |  read more...
USD 7,600
R&D Trends: Non-Small Cell Lung Cancer - Mutation analyses continue driving treatment choices
4/10/2012 | published by: CHI Insight Pharma Reports
... and tumor specific antigens. Features and benefits Analysis of the non-small cell lung cancer pipeline – development stage, therapeutic class, molecular targets, and changes in the last two years. In-depth analysis of current comparator therapy ...  |  read more...
USD 3,800
Epidemiology: Malignant Melanoma
4/5/2012 | published by: CHI Insight Pharma Reports
... growth and will be strongest in the US and the five major EU markets. Malignant melanoma is rare in Japan and will increase more slowly over the forecast period. Features and benefits Gain insight into ...  |  read more...
USD 5,700
Backup Compound Strategies: Commercial and Tactical Considerations - Overview
4/1/2012 | published by: CHI Insight Pharma Reports
... significant investments. Planning optimal backup compound strategies is often difficult. This Insight Pharma Report: Describes how companies are addressing strategic and tactical issues concerning backup compounds and predicts how they are likely to do so ...  |  read more...
USD 9,950
Fragment-Based Drug Discovery: Technologies, Applications, and Pipelines - Overview
4/1/2012 | published by: CHI Insight Pharma Reports
... Drug Discovery: Technologies, Applications, and Pipelines, examines the many issues that must be considered vis-à-vis employment of fragment-based screening approaches. Chemical considerations are examined, including the impact of high-throughput screening (HTS) and its attendant shortcomings, ...  |  read more...
USD 795
< prev 1    
 
US: 800.298.5699
Int'l: +1.240.747.3093
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!